The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1: A Randomized Trial
Open accessAbstract
IMPORTANCE: Patients co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are at high risk for liver disease progression. However, interferon-based treatments for HCV infection have significant toxicities, limiting treatment uptake. OBJECTIVE: To assess the all-oral 3 direct-acting antiviral (3D) regimen of ombitasvir, paritaprevir (co-dosed with ritonavir [paritaprevir/r]), dasabuvir, and ribavirin in HCV genotype 1-infected adults with HIV-1 co-infection, including patients with cirrhosis. DESIGN, SETTING, AND PARTICIPANTS: TURQUOISE-I is a randomized, open-label study. Part 1a of this pilot study was conducted at 17 sites in the United States and Puerto Rico between September 2013 and August 2014 and included 63 patients with HCV genotype 1 and HIV-1 co-infection who were HCV treatment-naive or had history of prior treatment failure with peginterferon plus ribavirin therapy. The study allowed enrollment of patients, including those with cirrhosis, with a CD4+ count of 200/mm3 or greater or CD4+ percentage of 14% or more and plasma HIV-1 RNA suppressed while taking a stable atazanavir- or raltegravir-inclusive antiretroviral regimen. INTERVENTIONS: Ombitasvir/paritaprevir/r, dasabuvir, and ribavirin for 12 or 24 weeks of treatment as randomized. MAIN OUTCOMES AND MEASURES: The primary assessment was the proportion of patients with sustained virologic response (HCV RNA <25 IU/mL) at posttreatment week 12 (SVR12). RESULTS: Among patients receiving 12 or 24 weeks of 3D and ribavirin, SVR12 was achieved by 29 of 31 (94%; 95% CI, 79%-98%) and 29 of 32 patients (91%; 95% CI, 76%-97%), respectively. Of the 5 patients who did not achieve SVR, 1 withdrew consent, 2 had confirmed virologic relapse or breakthrough, and 2 patients had clinical history and phylogenetic evidence consistent with HCV reinfection. The most common treatment-emergent adverse events were fatigue (48%), insomnia (19%), nausea (18%), and headache (16%). Adverse events were generally mild, with none reported as serious or leading to discontinuation. No patient had a confirmed HIV-1 breakthrough of 200 copies/mL or greater during treatment. CONCLUSIONS AND RELEVANCE: In this open-label, randomized uncontrolled study, treatment with the all-oral, interferon-free 3D-plus-ribavirin regimen resulted in high SVR rates among patients co-infected with HCV genotype 1 and HIV-1 whether treated for 12 or 24 weeks. Further phase 3 studies of this regimen are warranted in patients with co-infection. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01939197.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Correspondence - Tranexamic acid for traumatic brain injury
(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Afdhal, N., Reddy, K. R., Nelson, D. R., Lawitz, E., Gordon, S. C., Schiff, E., Nahass, R., Ghalib, R., Gitlin, N., Herring, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316366 · Cited by 1,307
Self-citationTorriani, F. J., Rodriguez-Torres, M., Rockstroh, J. K., Lissen, E., Gonzalez-García, J., Lazzarin, A., Carosi, G., Sasadeusz, J., Katlama, C., Montaner, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040842 · Cited by 1,233
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
Kitahata, M. M., Gange, S. J., Abraham, A. G., Merriman, B., Saag, M. S., Justice, A. C., Hogg, R. S., Deeks, S. G., Eron, J. J., Brooks, J. T., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807252 · Cited by 1,105
Self-citationGraham, C. S., Baden, L. R., Yu, E., Mrus, J. M., Carnie, J., Heeren, T., & Koziel, M. J. (2001) · Clinical Infectious Diseases · doi:10.1086/321909 · Cited by 974
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
Feld, J. J., Kowdley, K. V., Coakley, E., Sigal, S., Nelson, D. R., Crawford, D., Weiland, O., Aguilar, H., Xiong, J., Pilot-Matias, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315722 · Cited by 903
Self-citationABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
Poordad, F., Hezode, C., Trinh, R., Kowdley, K. V., Zeuzem, S., Agarwal, K., Shiffman, M. L., Wedemeyer, H., Berg, T., Yoshida, E. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402869 · Cited by 874
Self-citationSoto, B., Sánchez-Quijano, A., Rodrigo, L., Olmo, J. A. D., García-Bengoechea, M., Hernández-Quero, J., Rey, C., Abad, M. A., Rodríguez, M., Sales Gilabert, M., et al. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80001-3 · Cited by 701
ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Ferenci, P., Bernstein, D., Lalezari, J., Cohen, D., Luo, Y., Cooper, C., Tam, E., Marinho, R. T., Tsai, N., Nyberg, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402338 · Cited by 693
Self-citationRetreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
Zeuzem, S., Jacobson, I. M., Baykal, T., Marinho, R. T., Poordad, F., Bourlière, M., Sulkowski, M. S., Wedemeyer, H., Tam, E., Desmond, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401561 · Cited by 517
Self-citationTolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial
Bodenheimer, H. C., Lindsay, K. L., Davis, G. L., Lewis, J. H., Thung, S. N., & Seeff, L. B. (1997) · Hepatology · doi:10.1002/hep.510260231 · Cited by 380
Andreone, P., Colombo, M. G., Enejosa, J. V., Koksal, I., Ferenci, P., Maieron, A., Müllhaupt, B., Horsmans, Y., Weiland, O., Reesink, H. W., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.04.045 · Cited by 365
Self-citationPrevalence and Predictive Value of Intermittent Viremia With Combination HIV Therapy
Havlir, D. V. (2001) · JAMA · doi:10.1001/jama.286.2.171 · Cited by 358
Sulkowski, M., Hezode, C., Gerstoft, J., Vierling, J. M., Mallolas, J., Pol, S., Kugelmas, M., Murillo, A., Weis, N., Nahass, R., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61793-1 · Cited by 280
Self-citationFried, M. W., Buti, M., Dore, G. J., Flisiak, R., Ferenci, P., Jacobson, I., Marcellin, P., Manns, M., Nikitin, I., Poordad, F., et al. (2013) · Hepatology · doi:10.1002/hep.26641 · Cited by 272
Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
Sulkowski, M. S., Naggie, S., Lalezari, J., Fessel, W. J., Mounzer, K., Shuhart, M., Luetkemeyer, A. F., Asmuth, D., Gaggar, A., Ni, L., et al. (2014) · JAMA · doi:10.1001/jama.2014.7734 · Cited by 254
Self-citationRe, V. L., Kallan, M. J., Tate, J. P., Localio, A. R., Lim, J. K., Goetz, M. B., Klein, M. B., Rimland, D., Rodriguez-Barradas, M. C., Butt, A. A., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1829 · Cited by 248
Limketkai, B. N., Mehta, S. H., Sutcliffe, C. G., Higgins, Y. M., Torbenson, M. S., Brinkley, S. C., Moore, R. D., Thomas, D. L., & Sulkowski, M. S. (2012) · JAMA · doi:10.1001/jama.2012.7844 · Cited by 202
Self-citationSulkowski, M. S., Sherman, K. E., Dieterich, D. T., Bsharat, M., Mahnke, L., Rockstroh, J. K., Gharakhanian, S., McCallister, S., Henshaw, J., Girard, P.-M., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-2-201307160-00654 · Cited by 201
Self-citationHepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM
Martin, T. C. S., Martin, N. K., Hickman, M., Vickerman, P., Page, E. E., Everett, R., Gazzard, B. G., & Nelson, M. (2013) · AIDS · doi:10.1097/qad.0b013e32836381cc · Cited by 168
Rodriguez‐Torres, M., Slim, J., Bhatti, L., Sterling, R. K., Sulkowski, M., Hassanein, T., Serrão, R., Sola, R. L., Bertasso, A., Passe, A. S., et al. (2012) · HIV Clinical Trials · doi:10.1310/hct1303-142 · Cited by 65
Self-citationZhang, S., van Sighem, A., Gras, L. A., Reiss, P., Smit, C., Kroon, F. P., Jurriaans, S., Prins, J. M., Lange, J. M. A., & de Wolf, F. (2010) · Antiviral Therapy · doi:10.3851/imp1564 · Cited by 14
Cited by
Panel, A. H. G. (2015) · Hepatology · doi:10.1002/hep.27950 · Cited by 1,382
Panel, A.-I. H. G., Chung, R. T., Ghany, M. G., Kim, A. Y., Marks, K. M., Naggie, S., Vargas, H. E., Aronsohn, A. I., Bhattacharya, D., Broder, T., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy585 · Cited by 717
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review
Falade-Nwulia, O., Suarez-Cuervo, C., Nelson, D. R., Fried, M. W., Segal, J. B., & Sulkowski, M. S. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2575 · Cited by 688
Self-citationDaclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
Wyles, D. L., Ruane, P. J., Sulkowski, M. S., Dieterich, D., Luetkemeyer, A., Morgan, T. R., Sherman, K. E., Dretler, R., Fishbein, D., Gathe, J. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503153 · Cited by 419
Self-citationKhan, R. J., Jha, R. K., Amera, G. M., Jain, M., Singh, E., Pathak, A., Singh, R. P., Muthukumaran, J., & Singh, A. K. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1753577 · Cited by 343
Metadata
- Authors
- Sulkowski, M. S., Eron, J. J., Wyles, D., Trinh, R., Lalezari, J., Wang, C., Slim, J., Bhatti, L., Gathe, J., Ruane, P. J., Elion, R., Bredeek, F., Brennan, R., Blick, G., Khatri, A., Gibbons, K., Hu, Y. B., Fredrick, L., Schnell, G., Pilot-Matias, T., Tripathi, R., Da Silva-Tillmann, B., McGovern, B., Campbell, A. L., & Podsadecki, T.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2015-03-24
- Volume
- 313
- Issue
- 12
- Pages
- 1223
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2047156711
- Cited by
- 303
- References
- 23
- FWCI
- 41.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.